NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
Dollar Gains on Safe-Haven Demand as Iran Tensions and Inflation Data Loom 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Asian Stocks Slip as Korea’s KOSPI Tumbles Amid Iran Conflict and Chip Sector Profit-Taking 
Tabletop particle accelerator could transform medicine and materials science 
Trump-Iran Tensions Keep Oil Prices Elevated Amid Hormuz Supply Fears 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
